Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Cancer immunology, immunotherapy: CII [Cancer Immunol Immunother] NLMUID: 8605732"" wg kryterium: JN


Tytuł:
Clinical evidence for efficacy of pembrolizumab in MSI-H and TMB-H advanced solid tumor: results from three cancer centers in China.
Autorzy:
Yan H; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.; Graduate Collaborative Training Base of Hunan Cancer Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Song L; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.; Graduate Collaborative Training Base of Hunan Cancer Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.; Department of Medical Oncology, Yiyang Central Hospital, Yiyang, 413000, China.
Li Y; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.
Xu Q; Department of Medical Oncology, Qinghai Provincial People's Hospital, Xining, 810000, China.
Guo W; Department of Pathology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 20025, China.
Lin S; Department of Medical Oncology, The First Affiliated Hospital of Hunan University of Medicine, Huaihua, 418000, China.
Jiang W; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.
Wang Z; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.
Deng L; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.
Huang Z; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.
Qin H; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.; Graduate Collaborative Training Base of Hunan Cancer Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Zhang X; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.; Graduate Collaborative Training Base of Hunan Cancer Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Tong F; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Zhang R; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Liu Z; Department of Medical Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, 410008, Hunan, China.
Zhang L; Department of Radiotherapy, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, 410008, Hunan, China.
Yu J; Department of Medical Oncology, Zhangjiajie People's Hospital, Zhangjiajie, 410008, Hunan, China.
Dong X; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Gong Q; Department of Good Clinical Trials, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, 410008, Hunan, China.
Deng J; Early Clinical Trails Center, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, 410008, Hunan, China.
Chen X; Early Clinical Trails Center, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, 410008, Hunan, China.
Wang J; Early Clinical Trails Center, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, 410008, Hunan, China.
Zhang G; Faculty of Dentistry, The University of Hong Kong, 34 Hospital Road, Sai Ying Pun, 999077, Hong Kong.
Yang N; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.; Graduate Collaborative Training Base of Hunan Cancer Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Zhang Y; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China. .; Graduate Collaborative Training Base of Hunan Cancer Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China. .; Early Clinical Trails Center, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, 410008, Hunan, China. .; Furong Laboratory, Changsha, 410000, Hunan, China. .
Zeng L; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China. .
Pokaż więcej
Źródło:
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Mar 07; Vol. 73 (4), pp. 74. Date of Electronic Publication: 2024 Mar 07.
Typ publikacji:
Journal Article
MeSH Terms:
Microsatellite Instability*
Neoplasms*/drug therapy
Neoplasms*/genetics
Antibodies, Monoclonal, Humanized*
Humans ; Retrospective Studies ; China ; Pathologic Complete Response
Czasopismo naukowe
Tytuł:
Size selection of intrahepatic lesions for cryoablation contributes to abscopal effect and long-term survival in patients with liver metastatic melanoma receiving PD-1 blockade therapy.
Autorzy:
Shen L; Department of Minimally Invasive Interventional Therapy, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
Tan H; Department of Minimally Invasive Interventional Therapy, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
Nie J; Department of Research & Education, Guangzhou Concord Cancer Center, Guangzhou, 510054, People's Republic of China.
Jiang Y; Department of Minimally Invasive Interventional Therapy, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
Nuerhashi G; Department of Minimally Invasive Interventional Therapy, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
Qi H; Department of Minimally Invasive Interventional Therapy, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
Cao F; Department of Minimally Invasive Interventional Therapy, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
Wen C; Department of Minimally Invasive Interventional Therapy, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
Chen S; Department of Oncology, Yuebei People's Hospital, Shaoguan, 511100, People's Republic of China.
Zhang T; Department of Minimally Invasive Interventional Therapy, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
Zheng W; Chongqing Emergency Medical Center, Chongqing University Central Hospital, Chongqing, 400000, People's Republic of China.
Liu P; Department of Oncology, General Hospital of Southern Theater Command, Guangzhou, 510060, People's Republic of China.
Liu Y; Department of Minimally Invasive Interventional Therapy, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
Huang T; Department of Minimally Invasive Interventional Therapy, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
Li D; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.; Department of Biological Therapy Center, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
Zhang X; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China. .; Department of Biological Therapy Center, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China. .
Fan W; Department of Minimally Invasive Interventional Therapy, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China. .; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China. .
Pokaż więcej
Źródło:
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Mar 02; Vol. 73 (4), pp. 68. Date of Electronic Publication: 2024 Mar 02.
Typ publikacji:
Journal Article
MeSH Terms:
Cryosurgery*
Liver Neoplasms*/secondary
Liver Neoplasms*/surgery
Melanoma*/pathology
Humans ; Programmed Cell Death 1 Receptor ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Clinical immunotherapy in pancreatic cancer.
Autorzy:
Ye X; Department of Gastroenterology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, Anhui Province, People's Republic of China.
Yu Y; Department of Gastroenterology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, Anhui Province, People's Republic of China. .
Zheng X; Department of Neurosurgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, Anhui Province, People's Republic of China. .; Hefei National Research Center for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, People's Republic of China. .; Key Laboratory of Quantitative Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, People's Republic of China. .
Ma H; Hefei National Research Center for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, People's Republic of China. .; Department of Pediatrics, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, Anhui Province, People's Republic of China. .
Pokaż więcej
Źródło:
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Mar 02; Vol. 73 (4), pp. 64. Date of Electronic Publication: 2024 Mar 02.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Pancreatic Neoplasms*/pathology
Antineoplastic Agents*/therapeutic use
Humans ; Immunotherapy/methods ; T-Lymphocytes ; Treatment Outcome ; Tumor Microenvironment
Czasopismo naukowe
Tytuł:
Riboflavin-LSD1 axis participates in the in vivo tumor-associated macrophage morphology in human colorectal liver metastases.
Autorzy:
Soldani C; Laboratory of Hepatobiliary Immunopathology, IRCCS Humanitas Research Hospital, Via Alessandro Manzoni 56, 20089, Rozzano, Milan, Italy.
De Simone G; Laboratory of Metabolites and Proteins in Translational Research, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156, Milan, Italy.; Department of Biotechnologies and Biosciences, Università degli Studi Milano Bicocca, Milan, Italy.
Polidoro MA; Laboratory of Hepatobiliary Immunopathology, IRCCS Humanitas Research Hospital, Via Alessandro Manzoni 56, 20089, Rozzano, Milan, Italy.
Morabito A; Laboratory of Metabolites and Proteins in Translational Research, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156, Milan, Italy.; Department of Electronics, Information and Bioengineering, Politecnico di Milano, Milan, Italy.
Franceschini B; Laboratory of Hepatobiliary Immunopathology, IRCCS Humanitas Research Hospital, Via Alessandro Manzoni 56, 20089, Rozzano, Milan, Italy.
Colombo FS; Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Struttura Complessa di Patologia Clinica, Laboratorio di Citometria, Milano, Italy.
Anselmo A; Flow Cytometry Resource, Advanced Cytometry Technical Application Laboratory, IRCCS Ospedale San Raffaele, Milano, Italy.
Milana F; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele - Milan, Italy.; Division of Hepatobiliary and General Surgery, Department of Surgery, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089, Rozzano, Milan, Italy.
Lleo A; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele - Milan, Italy.; Division of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Torzilli G; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele - Milan, Italy.; Division of Hepatobiliary and General Surgery, Department of Surgery, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089, Rozzano, Milan, Italy.
Pastorelli R; Laboratory of Metabolites and Proteins in Translational Research, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156, Milan, Italy.
Donadon M; Laboratory of Hepatobiliary Immunopathology, IRCCS Humanitas Research Hospital, Via Alessandro Manzoni 56, 20089, Rozzano, Milan, Italy. .; Division of Hepatobiliary and General Surgery, Department of Surgery, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089, Rozzano, Milan, Italy. .; Department of Health Sciences, Università del Piemonte Orientale, Novara, Italy. .; Department of General Surgery, University Maggiore Hospital, Novara, Italy. .
Brunelli L; Laboratory of Metabolites and Proteins in Translational Research, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156, Milan, Italy. .
Pokaż więcej
Źródło:
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Mar 02; Vol. 73 (4), pp. 63. Date of Electronic Publication: 2024 Mar 02.
Typ publikacji:
Journal Article
MeSH Terms:
Liver Neoplasms*/pathology
Colorectal Neoplasms*/pathology
Humans ; Tumor-Associated Macrophages/metabolism ; Macrophages/metabolism ; Prognosis ; Tumor Microenvironment ; Membrane Transport Proteins/metabolism
Czasopismo naukowe
Tytuł:
Construction of an immune predictive model and identification of TRIP6 as a prognostic marker and therapeutic target of CRC by integration of single-cell and bulk RNA-seq data.
Autorzy:
Liu W; The First Department of General Surgery, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510150, Guangdong, China.
Luo X; The First Department of General Surgery, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510150, Guangdong, China.
Zhang Z; Department of Anorectal Surgery, The First People's Hospital of Foshan, Guangdong, 528010, China.
Chen Y; The First Department of General Surgery, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510150, Guangdong, China.
Dai Y; The First Department of General Surgery, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510150, Guangdong, China.
Deng J; Department of Anorectal Surgery, The First People's Hospital of Foshan, Guangdong, 528010, China.
Yang C; The First Department of General Surgery, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510150, Guangdong, China.
Liu H; Division of Vascular and Interventional Radiology, Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, 510000, Guangdong, China. .
Pokaż więcej
Źródło:
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Mar 02; Vol. 73 (4), pp. 69. Date of Electronic Publication: 2024 Mar 02.
Typ publikacji:
Journal Article
MeSH Terms:
Colorectal Neoplasms*/diagnosis
Colorectal Neoplasms*/therapy
Immunotherapy*
Humans ; Adaptor Proteins, Signal Transducing ; LIM Domain Proteins ; Prognosis ; RNA-Seq ; Sequence Analysis, RNA ; Transcription Factors
Czasopismo naukowe
Tytuł:
Integrating molecular subtype and CD8 T cells infiltration to predict treatment response and survival in muscle-invasive bladder cancer.
Autorzy:
Li B; Department of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Jin K; NHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.; Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Liu Z; NHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
Su X; NHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Xu Z; NHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Liu G; NHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Xu J; Department of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Liu H; Department of Urology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Chang Y; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
Wang Y; Department of Urology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhu Y; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
Wang Z; Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Xu L; Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhang W; Department of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China. .
Pokaż więcej
Źródło:
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Mar 02; Vol. 73 (4), pp. 66. Date of Electronic Publication: 2024 Mar 02.
Typ publikacji:
Journal Article
MeSH Terms:
CD8-Positive T-Lymphocytes*
Urinary Bladder Neoplasms*/drug therapy
Urinary Bladder Neoplasms*/genetics
Humans ; Prognosis ; Biomarkers, Tumor/genetics ; Muscles/pathology
Czasopismo naukowe
Tytuł:
Neutrophils seeking new neighbors: radiotherapy affects the cellular framework and the spatial organization in a murine breast cancer model.
Autorzy:
Reichardt CM; Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Ulmenweg 18, 91054, Erlangen, Germany.; Deutsches Zentrum Für Immuntherapie (DZI), Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.
Muñoz-Becerra M; Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Ulmenweg 18, 91054, Erlangen, Germany.; Deutsches Zentrum Für Immuntherapie (DZI), Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.
Rius Rigau A; Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Ulmenweg 18, 91054, Erlangen, Germany.; Deutsches Zentrum Für Immuntherapie (DZI), Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.
Rückert M; Translational Radiobiology, Department of Radiation Oncology, Universitätsklinikum Erlangen, FAU Erlangen-Nürnberg, Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
Fietkau R; Deutsches Zentrum Für Immuntherapie (DZI), Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.; Department of Radiation Oncology, Universitätsklinikum Erlangen, FAU Erlangen-Nürnberg, Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
Schett G; Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Ulmenweg 18, 91054, Erlangen, Germany.; Deutsches Zentrum Für Immuntherapie (DZI), Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.
Gaipl US; Deutsches Zentrum Für Immuntherapie (DZI), Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.; Translational Radiobiology, Department of Radiation Oncology, Universitätsklinikum Erlangen, FAU Erlangen-Nürnberg, Erlangen, Germany.; Department of Radiation Oncology, Universitätsklinikum Erlangen, FAU Erlangen-Nürnberg, Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
Frey B; Deutsches Zentrum Für Immuntherapie (DZI), Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.; Translational Radiobiology, Department of Radiation Oncology, Universitätsklinikum Erlangen, FAU Erlangen-Nürnberg, Erlangen, Germany.; Department of Radiation Oncology, Universitätsklinikum Erlangen, FAU Erlangen-Nürnberg, Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
Muñoz LE; Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Ulmenweg 18, 91054, Erlangen, Germany. .; Deutsches Zentrum Für Immuntherapie (DZI), Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany. .
Pokaż więcej
Źródło:
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Mar 02; Vol. 73 (4), pp. 67. Date of Electronic Publication: 2024 Mar 02.
Typ publikacji:
Journal Article
MeSH Terms:
Neoplasms*
Extracellular Traps*
Mice ; Animals ; Neutrophils ; Tumor Microenvironment
Czasopismo naukowe
Tytuł:
Oct4 activates IL-17A to orchestrate M2 macrophage polarization and cervical cancer metastasis.
Autorzy:
Bian Z; Department of the Fifth Rheumatology, The Fifth Hospital of Xi'an City, Xi'an, 710000, Shaanxi, China.
Wu X; Department of Obstetrics and Gynecology, Second Affiliated Hospital, Xi'an Jiao Tong University, 157 West Fifth Road, Xincheng District, Xi'an, 710000, Shaanxi, China.
Chen Q; Department of Obstetrics and Gynecology, Second Affiliated Hospital, Xi'an Jiao Tong University, 157 West Fifth Road, Xincheng District, Xi'an, 710000, Shaanxi, China.
Gao Q; Department of Obstetrics and Gynecology, Second Affiliated Hospital, Xi'an Jiao Tong University, 157 West Fifth Road, Xincheng District, Xi'an, 710000, Shaanxi, China.
Xue X; Department of Obstetrics and Gynecology, Second Affiliated Hospital, Xi'an Jiao Tong University, 157 West Fifth Road, Xincheng District, Xi'an, 710000, Shaanxi, China.
Wang Y; Department of Obstetrics and Gynecology, Second Affiliated Hospital, Xi'an Jiao Tong University, 157 West Fifth Road, Xincheng District, Xi'an, 710000, Shaanxi, China. wangyidong_.
Pokaż więcej
Źródło:
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Mar 02; Vol. 73 (4), pp. 73. Date of Electronic Publication: 2024 Mar 02.
Typ publikacji:
Journal Article
MeSH Terms:
Uterine Cervical Neoplasms*/metabolism
Uterine Cervical Neoplasms*/pathology
Octamer Transcription Factor-3*/metabolism
Female ; Humans ; Interleukin-17/metabolism ; Macrophages/metabolism
Czasopismo naukowe
Tytuł:
Combination of IL-33 with PD-1 blockade augment mILC2s-mediated anti-tumor immunity.
Autorzy:
Yue J; Department of Orthopaedics, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu, China.
Guo H; Department of Laboratory Medicine, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu, China.
Xu P; Department of Orthopaedics, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu, China.
Ma J; Department of Laboratory Medicine, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu, China.
Shi W; Department of Laboratory Medicine, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu, China. .
Wu Y; Department of Laboratory Medicine, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu, China. .; Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Institute of Nano and Soft Materials (FUNSOM) College of Nano Science &Technology (CNST) Suzhou, Jiangsu, 215123, China. .
Pokaż więcej
Źródło:
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Mar 02; Vol. 73 (4), pp. 65. Date of Electronic Publication: 2024 Mar 02.
Typ publikacji:
Journal Article
MeSH Terms:
Immunity, Innate*
Neoplasms*/therapy
Humans ; Mice ; Animals ; Lymphocytes ; Interleukin-33 ; Programmed Cell Death 1 Receptor ; Interleukin-1 Receptor-Like 1 Protein
Czasopismo naukowe
Tytuł:
Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma.
Autorzy:
Seiwert TY; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Wildsmith S; Oncology R&D, AstraZeneca, Cambridge, UK. .
Fayette J; Centre de Lutte Contre le Cancer Léon Bérard, Lyon-I University, Lyon, France.
Harrington K; Division of Radiotherapy and Imaging, The Royal Marsden/The Institute of Cancer Research NIHR Biomedical Research Centre, London, UK.
Gillison M; Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ahn MJ; Division of Hematology-Oncology, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea.
Takahashi S; Department of Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Weiss J; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Machiels JP; Department of Medical Oncology, Institut Roi Albert II, Cliniques Universitaires Saint-Luc and Institute for Experimental and Clinical Research (IREC, pôle MIRO), Université Catholique de Louvain (UCLouvain), Brussels, Belgium.
Baxi S; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Baker V; Oncology R&D, AstraZeneca, Cambridge, UK.
Evans B; Statistics, AstraZeneca, Gaithersburg, MD, USA.
Morsli N; Oncology R&D, AstraZeneca, Cambridge, UK.
Jill Walker; Oncology R&D, AstraZeneca, Cambridge, UK.
Real K; Oncology R&D, AstraZeneca, Cambridge, UK.
L'Hernault A; Oncology R&D, AstraZeneca, Cambridge, UK.
Psyrri A; Department of Internal Medicine, Section of Medical Oncology, Attikon University Hospital, National Kapodistrian University of Athens, Athens, Greece.
Pokaż więcej
Źródło:
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Mar 02; Vol. 73 (4), pp. 70. Date of Electronic Publication: 2024 Mar 02.
Typ publikacji:
Journal Article
MeSH Terms:
B7-H1 Antigen*/metabolism
Head and Neck Neoplasms*/drug therapy
Antibodies, Monoclonal*
Antibodies, Monoclonal, Humanized*
Humans ; Squamous Cell Carcinoma of Head and Neck/drug therapy ; Treatment Outcome ; Biomarkers, Tumor/metabolism
Czasopismo naukowe
Tytuł:
Ectopic CXCR2 expression cells improve the anti-tumor efficiency of CAR-T cells and remodel the immune microenvironment of pancreatic ductal adenocarcinoma.
Autorzy:
Dai Z; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, No. 270 Dong An Road, Xu-Hui District, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Pancreatic Cancer Institute, Shanghai, 200032, China.; Pancreatic Cancer Institute, Fudan University, Shanghai, 200032, China.
Lin X; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, No. 270 Dong An Road, Xu-Hui District, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Pancreatic Cancer Institute, Shanghai, 200032, China.; Pancreatic Cancer Institute, Fudan University, Shanghai, 200032, China.
Wang X; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, No. 270 Dong An Road, Xu-Hui District, Shanghai, 200032, China. .; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. .; Shanghai Pancreatic Cancer Institute, Shanghai, 200032, China. .; Pancreatic Cancer Institute, Fudan University, Shanghai, 200032, China. .; Cancer Research Institute, Shanghai Key Laboratory of Radiation Oncology, , Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China. .
Zou X; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, No. 270 Dong An Road, Xu-Hui District, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Pancreatic Cancer Institute, Shanghai, 200032, China.; Pancreatic Cancer Institute, Fudan University, Shanghai, 200032, China.
Yan Y; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, No. 270 Dong An Road, Xu-Hui District, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Pancreatic Cancer Institute, Shanghai, 200032, China.; Pancreatic Cancer Institute, Fudan University, Shanghai, 200032, China.
Wang R; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, No. 270 Dong An Road, Xu-Hui District, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Pancreatic Cancer Institute, Shanghai, 200032, China.; Pancreatic Cancer Institute, Fudan University, Shanghai, 200032, China.
Chen Y; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, No. 270 Dong An Road, Xu-Hui District, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Pancreatic Cancer Institute, Shanghai, 200032, China.; Pancreatic Cancer Institute, Fudan University, Shanghai, 200032, China.
Tasiheng Y; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, No. 270 Dong An Road, Xu-Hui District, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Pancreatic Cancer Institute, Shanghai, 200032, China.; Pancreatic Cancer Institute, Fudan University, Shanghai, 200032, China.
Ma M; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, No. 270 Dong An Road, Xu-Hui District, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Pancreatic Cancer Institute, Shanghai, 200032, China.; Pancreatic Cancer Institute, Fudan University, Shanghai, 200032, China.
Wang X; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, No. 270 Dong An Road, Xu-Hui District, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Pancreatic Cancer Institute, Shanghai, 200032, China.; Pancreatic Cancer Institute, Fudan University, Shanghai, 200032, China.
Cheng H; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, No. 270 Dong An Road, Xu-Hui District, Shanghai, 200032, China. .; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. .; Shanghai Pancreatic Cancer Institute, Shanghai, 200032, China. .; Pancreatic Cancer Institute, Fudan University, Shanghai, 200032, China. .
Yu X; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, No. 270 Dong An Road, Xu-Hui District, Shanghai, 200032, China. .; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. .; Shanghai Pancreatic Cancer Institute, Shanghai, 200032, China. .; Pancreatic Cancer Institute, Fudan University, Shanghai, 200032, China. .
Liu C; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, No. 270 Dong An Road, Xu-Hui District, Shanghai, 200032, China. .; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. .; Shanghai Pancreatic Cancer Institute, Shanghai, 200032, China. .; Pancreatic Cancer Institute, Fudan University, Shanghai, 200032, China. .
Pokaż więcej
Źródło:
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Mar 02; Vol. 73 (4), pp. 61. Date of Electronic Publication: 2024 Mar 02.
Typ publikacji:
Journal Article
MeSH Terms:
Receptors, Chimeric Antigen*
Pancreatic Neoplasms*/therapy
Carcinoma, Pancreatic Ductal*/therapy
Adenocarcinoma*
Humans ; Disease Progression ; Tumor Microenvironment
Czasopismo naukowe
Tytuł:
Mechanism exploration of Zoledronic acid combined with PD-1 in the treatment of hepatocellular carcinoma.
Autorzy:
Fan X; Department of Hepatobiliary Medicine, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, 200438, China.
Yan Z; Faculty of Hepato-Biliary-Pancreatic Surgery, The First Medical Center of Chinese People's Liberation, Army General Hospital, Beijing, 100039, China.
Lin Y; National Center for Liver Cancer, Shanghai, 201805, China.
Wang Q; Department of Hepatobiliary Medicine, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, 200438, China.
Jiang L; Department of Hepatobiliary Medicine, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, 200438, China.
Yao X; Department of Hepatobiliary Medicine, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, 200438, China.
Dong L; National Center for Liver Cancer, Shanghai, 201805, China.
Chen L; National Center for Liver Cancer, Shanghai, 201805, China.
Zhao T; Department of Hepatobiliary Medicine, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, 200438, China.
Zhao J; Outpatient Department, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, 200438, China.
Hu H; Department of Hepatobiliary Medicine, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, 200438, China. .
Wang H; Department of Hepatobiliary Medicine, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, 200438, China. .
Pokaż więcej
Źródło:
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Mar 02; Vol. 73 (4), pp. 62. Date of Electronic Publication: 2024 Mar 02.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/metabolism
Liver Neoplasms*/metabolism
Humans ; Animals ; Mice ; Zoledronic Acid/pharmacology ; Zoledronic Acid/therapeutic use ; Programmed Cell Death 1 Receptor ; Cell Line, Tumor ; Tumor Microenvironment
Czasopismo naukowe
Tytuł:
A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer.
Autorzy:
Falchook GS; Drug Development Unit, Sarah Cannon Research Institute at HealthONE, Denver, CO, USA. .
Reeves J; Florida Cancer Specialists South, Sarah Cannon Research Institute, Fort Meyers, FL, USA.
Gandhi S; Florida Cancer Specialists South, Sarah Cannon Research Institute, St. Petersberg, FL, USA.
Spigel DR; Tennessee Oncology, Sarah Cannon Research Institute, Nashville, TN, USA.
Arrowsmith E; Tennessee Oncology, Sarah Cannon Research Institute, Nashville, TN, USA.
George DJ; Duke Cancer Institute, Durham, NC, USA.
Karlix J; Sarah Cannon Research Institute, Gainesville, FL, USA.
Pouliot G; Oncology R&D, AstraZeneca, Waltham, MA, USA.
Hattersley MM; Oncology R&D, AstraZeneca, Waltham, MA, USA.
Gangl ET; BioPharma R&D, AstraZeneca, Boston, MA, USA.
James GD; Medical Statistics Consultancy Ltd, London, UK.
Thompson J; Oncology R&D, AstraZeneca, Waltham, MA, USA.
Russell DL; Oncology R&D, AstraZeneca, Waltham, MA, USA.
Patel B; Oncology R&D, AstraZeneca, Cambridge, UK.
Kumar R; Oncology R&D, AstraZeneca, Gaithersburg, MD, USA.
Lim E; Medical Oncology & Hematology-LHCP, Corewell Health Medical Group, Grand Rapids, MI, USA.
Pokaż więcej
Źródło:
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Mar 02; Vol. 73 (4), pp. 72. Date of Electronic Publication: 2024 Mar 02.
Typ publikacji:
Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article
MeSH Terms:
Prostatic Neoplasms, Castration-Resistant*
Antineoplastic Agents*/therapeutic use
Antibodies, Monoclonal*
Male ; Humans ; Prostate-Specific Antigen ; Fatigue ; Adenosine ; Nausea/drug therapy
Czasopismo naukowe
Tytuł:
Molecular classification reveals the sensitivity of lung adenocarcinoma to radiotherapy and immunotherapy: multi-omics clustering based on similarity network fusion.
Autorzy:
Zhang J; Department of Pulmonary Oncology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.
Li Y; Department of Pulmonary Oncology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.
Dai W; Department of Pulmonary Oncology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.
Tang F; Department of Pulmonary Oncology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.
Wang L; Department of Pulmonary Oncology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.
Wang Z; Department of Gastroenterology, Qingdao Municipal Hospital, Qingdao, 266000, Shandong, China.
Li S; Department of Pulmonary Oncology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.
Ji Q; Department of Pulmonary Oncology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.
Zhang J; Department of Pulmonary Oncology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.
Liao Z; Department of Pulmonary Oncology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.
Yu J; Department of Pulmonary Oncology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.
Xu Y; Department of Pulmonary Oncology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.
Gong J; Department of Pulmonary Oncology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.
Hu J; Department of Pulmonary Oncology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.
Li J; Department of Pulmonary Oncology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.
Guo X; Department of Pulmonary Oncology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.
He F; Department of Pulmonary Oncology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.
Han L; Department of Pulmonary Oncology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.
Gong Y; Tumor Precision Diagnosis and Treatment Technology and Translational Medicine, Hubei Engineering Research Center, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.; Human Genetics Resource Reservation Center, Wuhan University, Wuhan, 430071, Hubei, China.
Ouyang W; Department of Pulmonary Oncology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China. .; Hubei Key Laboratory of Tumour Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China. .
Wang Z; Department of Pulmonary Oncology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China. .; Hubei Key Laboratory of Tumour Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China. .
Xie C; Department of Pulmonary Oncology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China. chxie_.; Hubei Key Laboratory of Tumour Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China. chxie_.
Pokaż więcej
Źródło:
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Mar 02; Vol. 73 (4), pp. 71. Date of Electronic Publication: 2024 Mar 02.
Typ publikacji:
Journal Article
MeSH Terms:
Adenocarcinoma of Lung*/genetics
Adenocarcinoma of Lung*/therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/therapy
Humans ; Multiomics ; Immunotherapy ; Cluster Analysis ; Prognosis
Czasopismo naukowe
Tytuł:
Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells.
Autorzy:
Rajasekaran N; Coherus Biosciences, 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA. .
Wang X; Coherus Biosciences, 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA.
Ravindranathan S; Coherus Biosciences, 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA.
Chin DJ; Coherus Biosciences, 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA.
Tseng SY; Coherus Biosciences, 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA.
Klakamp SL; Coherus Biosciences, 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA.
Widmann K; Coherus Biosciences, 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA.
Kapoor VN; Coherus Biosciences, 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA.
Vexler V; Coherus Biosciences, 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA.
Keegan P; TopAlliance Biosciences, 9430 Key West Ave, Suite 125, Rockville, MD, 20850, USA.
Yao S; TopAlliance Biosciences, 9430 Key West Ave, Suite 125, Rockville, MD, 20850, USA.; Shanghai Junshi Biosciences, Shanghai, China.
LaVallee T; Coherus Biosciences, 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA.
Khare SD; Coherus Biosciences, 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA.
Pokaż więcej
Źródło:
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Feb 24; Vol. 73 (3), pp. 60. Date of Electronic Publication: 2024 Feb 24.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/drug therapy
Esophageal Neoplasms*/drug therapy
Esophageal Squamous Cell Carcinoma*/drug therapy
Nasopharyngeal Neoplasms*
Antibodies, Monoclonal, Humanized*
Humans ; Antibodies, Monoclonal/therapeutic use ; B7-H1 Antigen ; Programmed Cell Death 1 Receptor ; Nasopharyngeal Carcinoma ; T-Lymphocytes/pathology
Czasopismo naukowe
Tytuł:
Multiplexed analysis of macrophage polarisation in pulmonary metastases of microsatellite stable colorectal cancer.
Autorzy:
Karjula T; Translational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland. .
Elomaa H; Department of Biological and Environmental Science, University of Jyväskylä, 40014, Jyväskylä, Finland.; Department of Education and Research, Hospital Nova of Central Finland, Well Being Services County of Central Finland, 40620, Jyväskylä, Finland.
Väyrynen SA; Department of Internal Medicine, Oulu University Hospital, Oulu, Finland.
Kuopio T; Department of Biological and Environmental Science, University of Jyväskylä, 40014, Jyväskylä, Finland.; Department of Pathology, Hospital Nova of Central Finland, Well Being Services County of Central Finland, 40620, Jyväskylä, Finland.
Ahtiainen M; Department of Pathology, Hospital Nova of Central Finland, Well Being Services County of Central Finland, 40620, Jyväskylä, Finland.
Mustonen O; Translational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.
Puro I; Translational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.
Niskakangas A; Translational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.
Mecklin JP; Department of Education and Research, Hospital Nova of Central Finland, Well Being Services County of Central Finland, 40620, Jyväskylä, Finland.; Faculty of Sport and Health Sciences, University of Jyväskylä, 40014, Jyväskylä, Finland.
Böhm J; Department of Pathology, Hospital Nova of Central Finland, Well Being Services County of Central Finland, 40620, Jyväskylä, Finland.
Wirta EV; Faculty of Medicine and Health Technology, Tampere University and TAYS Cancer Center, Tampere University Hospital, 33520, Tampere, Finland.; Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital and TAYS Cancer Centre, 33520, Tampere, Finland.
Seppälä TT; Department of Gastrointestinal Surgery, Helsinki University Central Hospital, University of Helsinki, 00290, Helsinki, Finland.; Applied Tumor Genomics, Research Program Unit, University of Helsinki, 00290, Helsinki, Finland.; Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital and TAYS Cancer Centre, 33520, Tampere, Finland.
Sihvo E; Central Hospital of Central Finland, 40014, Jyväskylä, Finland.
Yannopoulos F; Translational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.; Department of Cardiothoracic Surgery, Oulu University Hospital, Oulu, Finland.
Helminen O; Translational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.
Väyrynen JP; Translational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.
Pokaż więcej
Źródło:
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Feb 22; Vol. 73 (3), pp. 59. Date of Electronic Publication: 2024 Feb 22.
Typ publikacji:
Journal Article
MeSH Terms:
Lung Neoplasms*
Colorectal Neoplasms*/genetics
Humans ; Macrophage Activation ; Macrophages ; Microsatellite Repeats
Czasopismo naukowe
Tytuł:
Granzyme B+ B cells detected by single-cell sequencing are associated with prognosis in patients with intrahepatic cholangiocarcinoma following liver transplantation.
Autorzy:
Zhu JQ; Department of Hepatobiliary and Pancreaticosplenic Surgery, Beijing Organ Transplant Center, Beijing Chaoyang Hospital, Capital Medical University, No. 8 Gongtinan Road, Chaoyang District, Beijing, 100020, People's Republic of China.
Zhu Y; Department of Clinical Psychology, Mental Hospital of Jianqu Administration Bureau of Jiangsu Province, Nanjing, 210031, Jiangsu, People's Republic of China.
Qi M; Pathology Department, Beijing Chaoyang Hospital, Capital Medical University, Beijing, 100020, People's Republic of China.
Zeng Y; Clinical Lab, Tongji Medical College, Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Huazhong University of Science & Technology, Wuhan, 430070, Hubei, People's Republic of China.
Liu ZJ; Department of Infectious Diseases and Clinical Microbiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, 100020, People's Republic of China.
Ding C; Department of Hepatobiliary and Pancreaticosplenic Surgery, Beijing Organ Transplant Center, Beijing Chaoyang Hospital, Capital Medical University, No. 8 Gongtinan Road, Chaoyang District, Beijing, 100020, People's Republic of China.
Zhang T; Department of Hepatobiliary and Pancreaticosplenic Surgery, Beijing Organ Transplant Center, Beijing Chaoyang Hospital, Capital Medical University, No. 8 Gongtinan Road, Chaoyang District, Beijing, 100020, People's Republic of China.
Li XL; Department of Hepatobiliary and Pancreaticosplenic Surgery, Beijing Organ Transplant Center, Beijing Chaoyang Hospital, Capital Medical University, No. 8 Gongtinan Road, Chaoyang District, Beijing, 100020, People's Republic of China.
Han DD; Department of Hepatobiliary Surgery, China-Japan Friendship Hospital, No. 2 Yinghua East Street, Chaoyang District, Beijing, 100029, People's Republic of China. .
He Q; Department of Hepatobiliary and Pancreaticosplenic Surgery, Beijing Organ Transplant Center, Beijing Chaoyang Hospital, Capital Medical University, No. 8 Gongtinan Road, Chaoyang District, Beijing, 100020, People's Republic of China. .
Pokaż więcej
Źródło:
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Feb 22; Vol. 73 (3), pp. 58. Date of Electronic Publication: 2024 Feb 22.
Typ publikacji:
Journal Article
MeSH Terms:
Liver Transplantation*
Cholangiocarcinoma*/genetics
Cholangiocarcinoma*/surgery
Bile Duct Neoplasms*/genetics
Bile Duct Neoplasms*/surgery
Humans ; Granzymes/genetics ; Prognosis ; Bile Ducts, Intrahepatic ; Tumor Microenvironment
Czasopismo naukowe
Tytuł:
Targeting myeloperoxidase limits myeloid cell immunosuppression enhancing immune checkpoint therapy for pancreatic cancer.
Autorzy:
Basnet A; Department of Microbiology, Immunology, and Cell Biology, School of Medicine, West Virginia University, 64 Medical Center Drive, Morgantown, WV, 26506, USA.
Landreth KM; Department of Microbiology, Immunology, and Cell Biology, School of Medicine, West Virginia University, 64 Medical Center Drive, Morgantown, WV, 26506, USA.
Nohoesu R; Department of Microbiology, Immunology, and Cell Biology, School of Medicine, West Virginia University, 64 Medical Center Drive, Morgantown, WV, 26506, USA.
Santiago SP; Department of Pathology, Anatomy and Laboratory Medicine, West Virginia University, Morgantown, WV, 26506, USA.
Geldenhuys WJ; WVU Cancer Institute, West Virginia University, Morgantown, WV, 26506, USA.; Department of Pharmaceutical Sciences, West Virginia University, Morgantown, WV, 26506, USA.
Boone BA; WVU Cancer Institute, West Virginia University, Morgantown, WV, 26506, USA.; Division of Surgical Oncology, Department of Surgery, West Virginia University, Morgantown, WV, 26506, USA.
Liu TW; Department of Microbiology, Immunology, and Cell Biology, School of Medicine, West Virginia University, 64 Medical Center Drive, Morgantown, WV, 26506, USA. .; WVU Cancer Institute, West Virginia University, Morgantown, WV, 26506, USA. .
Pokaż więcej
Źródło:
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Feb 17; Vol. 73 (3), pp. 57. Date of Electronic Publication: 2024 Feb 17.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Pancreatic Ductal*/drug therapy
Carcinoma, Pancreatic Ductal*/metabolism
Pancreatic Neoplasms*/metabolism
Animals ; Humans ; Mice ; Immunosuppression Therapy ; Immunotherapy/methods ; Myeloid Cells ; Peroxidase/therapeutic use ; Reactive Oxygen Species/therapeutic use ; Tumor Microenvironment
Czasopismo naukowe
Tytuł:
Chemokine CCL21 determines immunotherapy response in hepatocellular carcinoma by affecting neutrophil polarization.
Autorzy:
Xu W; Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, 200032, People's Republic of China.
Weng J; Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, 200032, People's Republic of China.; Key Laboratory of Whole-Period Monitoring and Precise Intervention of Digestive Cancer of Shanghai Municipal Health Commission, Shanghai, 201199, People's Republic of China.
Xu M; Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, 200032, People's Republic of China.; Key Laboratory of Whole-Period Monitoring and Precise Intervention of Digestive Cancer of Shanghai Municipal Health Commission, Shanghai, 201199, People's Republic of China.
Zhou Q; Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, 200032, People's Republic of China.; Key Laboratory of Whole-Period Monitoring and Precise Intervention of Digestive Cancer of Shanghai Municipal Health Commission, Shanghai, 201199, People's Republic of China.
Liu S; Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, 200032, People's Republic of China.; Key Laboratory of Whole-Period Monitoring and Precise Intervention of Digestive Cancer of Shanghai Municipal Health Commission, Shanghai, 201199, People's Republic of China.
Hu Z; Key Laboratory of Whole-Period Monitoring and Precise Intervention of Digestive Cancer of Shanghai Municipal Health Commission, Shanghai, 201199, People's Republic of China.; Department of Hepatobiliary and Pancreatic Surgery, Minhang Hospital, Fudan University, Shanghai, 201199, People's Republic of China.; Institute of Fudan-Minhang Academic Health System, Minhang Hospital, Fudan University, Shanghai, 201199, People's Republic of China.
Ren N; Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, 200032, People's Republic of China. .; Key Laboratory of Whole-Period Monitoring and Precise Intervention of Digestive Cancer of Shanghai Municipal Health Commission, Shanghai, 201199, People's Republic of China. .; Institute of Fudan-Minhang Academic Health System, Minhang Hospital, Fudan University, Shanghai, 201199, People's Republic of China. .
Zhou C; Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, 200032, People's Republic of China. .; Key Laboratory of Whole-Period Monitoring and Precise Intervention of Digestive Cancer of Shanghai Municipal Health Commission, Shanghai, 201199, People's Republic of China. .
Shen Y; Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, 200032, People's Republic of China. .
Pokaż więcej
Źródło:
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Feb 17; Vol. 73 (3), pp. 56. Date of Electronic Publication: 2024 Feb 17.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/therapy
Liver Neoplasms*/therapy
Humans ; Chemokine CCL21 ; Neutrophils ; Immunotherapy ; Tumor Microenvironment
Czasopismo naukowe
Tytuł:
Induction immunotherapy plus chemotherapy followed by definitive chemoradiation therapy in locally advanced esophageal squamous cell carcinoma: a propensity-score matched study.
Autorzy:
Lian HM; Department of Radiation Oncology, The First Affiliated Hospital of Sun Yat-Sen University, 58 Zhongshan Road II, Guangzhou, 510080, Guangdong Province, China.
Wu JL; Department of Radiation Oncology, The First Affiliated Hospital of Sun Yat-Sen University, 58 Zhongshan Road II, Guangzhou, 510080, Guangdong Province, China.; Shenzhen Qianhai Taikang Hospital, Shenzhen, 518000, Guangdong Province, China.
Liufu WJ; Department of Radiation Oncology, The First Affiliated Hospital of Sun Yat-Sen University, 58 Zhongshan Road II, Guangzhou, 510080, Guangdong Province, China.
Yu TT; Department of Radiation Oncology, The First Affiliated Hospital of Sun Yat-Sen University, 58 Zhongshan Road II, Guangzhou, 510080, Guangdong Province, China.
Niu SQ; Department of Radiation Oncology, The First Affiliated Hospital of Sun Yat-Sen University, 58 Zhongshan Road II, Guangzhou, 510080, Guangdong Province, China.
Bao Y; Department of Radiation Oncology, The First Affiliated Hospital of Sun Yat-Sen University, 58 Zhongshan Road II, Guangzhou, 510080, Guangdong Province, China. .
Peng F; Department of Radiation Oncology, The First Affiliated Hospital of Sun Yat-Sen University, 58 Zhongshan Road II, Guangzhou, 510080, Guangdong Province, China. .
Pokaż więcej
Źródło:
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Feb 16; Vol. 73 (3), pp. 55. Date of Electronic Publication: 2024 Feb 16.
Typ publikacji:
Journal Article
MeSH Terms:
Esophageal Squamous Cell Carcinoma*/therapy
Esophageal Neoplasms*/therapy
Esophageal Neoplasms*/pathology
Humans ; Retrospective Studies ; Prospective Studies ; Propensity Score ; Chemoradiotherapy/methods ; Immunotherapy ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies